Business description
Evolva Holding SA (formerly Arpida AG) is a Swiss synthetic biology company, internationally active in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva uses biosynthetic and evolutionary technologies to artificially create and optimise small molecule compounds and their production routes. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. Evolva is active in consumer healthcare and nutrition as well as in pharma. In both areas they have partnered projects as well as own proprietary programmes.
Management board & Supervisory board
| CEO |
| Christian Wichert |
| Management board |
| Carsten Däweritz, Anne De Vos, Astrid Schäfer, Gerhard Lobmaier, Philipp Frech |
| Supervisory board |
| Stephan Schindler, Beat In-Albon, Christoph Breucker, Andreas Pfluger, Andreas Weigelt |
Company data
| Name: |
Evolva Holding SA |
| Address: |
Duggingerstraße 23,CH-4153 Reinach |
| Phone: |
+41-61-485-2000 |
| Fax: |
+41-61-485-2001 |
| E-mail: |
info@evolva.com
|
| Internet: |
www.evolva.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12/31 |
| Free Float: |
69.53% |
| IPO date: |
4/26/2023 |
Investor relations
| Name: |
Doris Rudischhauser |
| IR phone: |
+41-79-410-81-88 |
| IR Fax: |
- |
| IR e-mail: |
dorisr@evolva.com
|
